MedTrace Logo

Reduced Anticoagulation Targets in ECLS (RATE)

NCT04536272 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2025-05-02

No results posted yet for this study

Summary

The objective of the RATE-trial is to study if reduced anticoagulation targets during ECLS diminish bleeding complications without an increase in thromboembolic complications or a negative impact on outcome.

Conditions

Interventions

DRUG

Heparin

Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.

DRUG

LMWH

Administration of LMWH guided by weight and renal function during ECLS.

Sponsors & Collaborators

  • ZonMw: The Netherlands Organisation for Health Research and Development

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • Leiden University Medical Center

    collaborator OTHER

  • St. Antonius Hospital

    collaborator OTHER

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER

  • Isala

    collaborator OTHER

  • OLVG

    collaborator NETWORK

  • Radboud University Medical Center

    collaborator OTHER

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • W.M. van den Bergh, PhD, MD · University Medical Center Groningen

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2025-03-07
Completion
2025-03-07

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04536272 on ClinicalTrials.gov